The challenge of cardiomyopathies and heart failure in pregnancy
- 1 December 2018
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 30 (6) , 378-384
Abstract
Purpose of review: To discuss the risk preexisting or new onset cardiomyopathy/heart failure (CMP/heart failure) in pregnant woman, and recent insights regarding their management and therapy. Recent findings: Recent data from the European Registry on Pregnancy and Heart disease of the European Society of Cardiology (ROPAC) suggest that, after an adequate prepregnancy evaluation in specialized centres, the vast majority of pregnancies are safe for both mother and foetus. A tailored approach is required according to cardiac phenotype (i.e. type of cardiomyopathy), clinical and functional status, and new potential treatments (i.e. bromocriptine in patients with peripartum cardiomyopathy). Summary: In clinical practice, prepregnancy cardiac evaluation is mandatory, including evaluation of the clinical status, standard ECG (and 24–48 h monitoring, whenever required), and imaging, to define the individual risk profile. In presence of severe symptoms (advanced New York Heart Association class), cardiac dysfunction (moderate–severe reduced ejection fraction), haemodynamic load (left ventricular outflow tract obstruction, pulmonary hypertension), pregnancy is contraindicated. A tailored monitoring is warranted in other cases (mild–moderate risk pregnancies). Likewise, in women who develop PPCM, a risk stratification and tailored monitoring and therapy should be achieved by an expert, multidisciplinary team, including cardiologists, gynaecologists, obstetricians, genetic counsellor, and psychologists.Keywords
This publication has 46 references indexed in Scilit:
- Pregnancy in women with hypertrophic cardiomyopathyNetherlands Heart Journal, 2012
- ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)European Heart Journal, 2011
- Pregnancy in Patients With Pre-Existing CardiomyopathiesJACC, 2011
- Pregnancy and subsequent pregnancy outcomes in peripartum cardiomyopathyJournal of Obstetrics and Gynaecology Research, 2010
- Predictors of pregnancy complications in women with congenital heart diseaseEuropean Heart Journal, 2010
- Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum CardiomyopathyCirculation, 2010
- Clinical Profile and Predictors of Complications in Peripartum CardiomyopathyJournal of Cardiac Failure, 2009
- Pregnancy in high risk cardiac conditionsHeart, 2008
- A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum CardiomyopathyCell, 2007
- Risks of contraception and pregnancy in heart diseaseHeart, 2006